CE_Peptide_Map_Fingerprint

CE Peptide Map Fingerprint

Lumex QC URS & FS input.csv output.json rule-based LIMS-ready capillary electrophoresis
Open selection

Utility description: CE Peptide Map Fingerprint

CE Peptide Map Fingerprint — Peptide Mapping of Proteins (CE)

ℹ️  Utility checks critical parameters of recombinant protein peptide maps:
   • Peak Count: ≥20 (depends on protein and protease)
   • Sequence Coverage: ≥95.0%
   • Fingerprint Correlation with reference: ≥0.98
   • Novel/Unidentified Peaks Count: 0

⚠️  CRITICAL: Low correlation (<0.98) → protein structure or manufacturing process change!
   Appearance of novel peaks → degradation, oxidation, or misfolding.

Usage:
 CE_Peptide_Map_Fingerprint.exe                            → demo mode (console output)
 CE_Peptide_Map_Fingerprint.exe input.csv output.json      → evaluate your data

Input format:
BatchNumber,PeakCount,SequenceCoveragePercent,FingerprintCorrelation,MainPeakRelativeArea,NovelPeaksCount

Example:
 PEPMAP-CE-2026-001,45,98.5,0.995,100.0,0

— WHY IS THIS NEEDED?
Peptide mapping is one of the most stringent tests for identity and quality of protein drugs (mAb, insulin, hormones).
• Protein is digested by a specific protease (e.g., trypsin) into peptides.
• Capillary Electrophoresis (CE) separates peptides by charge and size with high resolution.
• The resulting profile ("fingerprint") is compared with a reference standard.
• Any deviation in the profile (peak shift, appearance/disappearance) indicates changes in primary structure or post-translational modifications.
• Compliance with USP <1053> and Ph. Eur. 2.2.47.

⚠️  CRITICAL:
• Sequence Coverage ≥95% ensures that the majority of the molecule is analyzed.
• Correlation ≥0.98 confirms batch identity to the standard.
• Absence of novel peaks is critical for detecting trace degradation products (deamidation, oxidation).
• Method requires high reproducibility of digestion and separation conditions.

Key features:
• Assessment of peptide map complexity (peak count).
• Calculation of sequence coverage.
• Statistical profile comparison (correlation).
• Control of artifacts or degradation products appearance.

Critical parameters:
• Peak Count: >= 20
• Sequence Coverage: >= 95.0%
• Fingerprint Correlation: >= 0.98
• Novel Peaks: 0

💡 Usage tips:
1. Use standardized proteolysis protocols (time, temperature, enzyme/substrate ratio).
2. Apply fluorescent labeling of peptides (e.g., FITC) for higher sensitivity.
3. Regularly perform System Suitability testing with a standard protein.
4. Compare profiles using specialized peak alignment software.
5. Pay attention to peaks characteristic of specific modifications (e.g., C-terminal lysine clipping for mAb).

⚠️ Note: Unlike mass spectrometry, CE does not provide direct mass information of peptides, but has superior resolution for isoforms and charge variants, making it a complementary method for quality control.

input.csv

BatchNumber,PeakCount,Coverage%,Correlation,MainArea%,NovelPeaks
PEPMAP-CE-2026-001,45,98.5,0.995,100.0,0
PEPMAP-CE-2026-002,44,97.8,0.992,99.5,0
PEPMAP-FAIL-2026-003,30,85.0,0.920,95.0,3

Utility description

CE Peptide Map Fingerprint — Peptide Mapping of Proteins (CE)

ℹ️  Utility checks critical parameters of recombinant protein peptide maps:
   • Peak Count: ≥20 (depends on protein and protease)
   • Sequence Coverage: ≥95.0%
   • Fingerprint Correlation with reference: ≥0.98
   • Novel/Unidentified Peaks Count: 0

⚠️  CRITICAL: Low correlation (<0.98) → protein structure or manufacturing process change!
   Appearance of novel peaks → degradation, oxidation, or misfolding.

Usage:
 CE_Peptide_Map_Fingerprint.exe                            → demo mode (console output)
 CE_Peptide_Map_Fingerprint.exe input.csv output.json      → evaluate your data

Input format:
BatchNumber,PeakCount,SequenceCoveragePercent,FingerprintCorrelation,MainPeakRelativeArea,NovelPeaksCount

Example:
 PEPMAP-CE-2026-001,45,98.5,0.995,100.0,0

— WHY IS THIS NEEDED?
Peptide mapping is one of the most stringent tests for identity and quality of protein drugs (mAb, insulin, hormones).
• Protein is digested by a specific protease (e.g., trypsin) into peptides.
• Capillary Electrophoresis (CE) separates peptides by charge and size with high resolution.
• The resulting profile ("fingerprint") is compared with a reference standard.
• Any deviation in the profile (peak shift, appearance/disappearance) indicates changes in primary structure or post-translational modifications.
• Compliance with USP <1053> and Ph. Eur. 2.2.47.

⚠️  CRITICAL:
• Sequence Coverage ≥95% ensures that the majority of the molecule is analyzed.
• Correlation ≥0.98 confirms batch identity to the standard.
• Absence of novel peaks is critical for detecting trace degradation products (deamidation, oxidation).
• Method requires high reproducibility of digestion and separation conditions.

Key features:
• Assessment of peptide map complexity (peak count).
• Calculation of sequence coverage.
• Statistical profile comparison (correlation).
• Control of artifacts or degradation products appearance.

Critical parameters:
• Peak Count: >= 20
• Sequence Coverage: >= 95.0%
• Fingerprint Correlation: >= 0.98
• Novel Peaks: 0

💡 Usage tips:
1. Use standardized proteolysis protocols (time, temperature, enzyme/substrate ratio).
2. Apply fluorescent labeling of peptides (e.g., FITC) for higher sensitivity.
3. Regularly perform System Suitability testing with a standard protein.
4. Compare profiles using specialized peak alignment software.
5. Pay attention to peaks characteristic of specific modifications (e.g., C-terminal lysine clipping for mAb).

⚠️ Note: Unlike mass spectrometry, CE does not provide direct mass information of peptides, but has superior resolution for isoforms and charge variants, making it a complementary method for quality control.

URS & FS — User Requirements and Functional Specification

This document describes the controlled interface, user requirements and functional behaviour of CE_Peptide_Map_Fingerprint. The utility is intended for automated verification of laboratory, pharmacopoeial, analytical or manufacturing QC parameters using input.csv and producing a structured output.json result.

Domain limits and critical parameters

Before production use, all limits must be verified against the approved specification, registration dossier, pharmacopoeial monograph, validated method and local SOPs.
  • • Peak Count: ≥20 (depends on protein and protease)
  • • Sequence Coverage: ≥95.0%
  • • Fingerprint Correlation with reference: ≥0.98
  • • Novel/Unidentified Peaks Count: 0
  • • Protein is digested by a specific protease (e.g., trypsin) into peptides.
  • • Capillary Electrophoresis (CE) separates peptides by charge and size with high resolution.
  • • The resulting profile ("fingerprint") is compared with a reference standard.
  • • Any deviation in the profile (peak shift, appearance/disappearance) indicates changes in primary structure or post-translational modifications.
  • • Compliance with USP <1053> and Ph. Eur. 2.2.47.
  • • Sequence Coverage ≥95% ensures that the majority of the molecule is analyzed.
  • • Correlation ≥0.98 confirms batch identity to the standard.
  • • Absence of novel peaks is critical for detecting trace degradation products (deamidation, oxidation).
  • • Method requires high reproducibility of digestion and separation conditions.
  • • Assessment of peptide map complexity (peak count).
  • • Calculation of sequence coverage.
  • • Statistical profile comparison (correlation).

URS — User Requirements Specification

IDRequirementCriticalityAcceptance criterion
URS-001The utility shall accept an input.csv file with exact headers defined in the data contract.HighThe file is processed without manual header editing.
URS-002The utility shall perform deterministic evaluation for CE Peptide Map Fingerprint using input values, approved limits and domain rules.HighEach row receives a PASS / WARNING / FAIL status.
URS-003The utility shall validate mandatory fields, data types, numeric ranges, units and domain plausibility.HighSchema, format and conversion errors are explicitly reported.
URS-004The utility shall identify critical deviations for parameters stated in the method description and specification.HighA critical deviation causes FAIL or a dedicated critical finding.
URS-005The utility shall generate output.json with machine-readable results, source values, warnings and failures.HighJSON is suitable for LIMS/ELN/MES integration, QA/QC review and archival.
URS-006The result shall not depend on machine learning or undocumented heuristics.MediumAll decisions are based on explicit rules, thresholds and input values.
URS-007The system shall preserve traceability between batch/sample, input data, applied rules and final status.HighThe output contains the batch/sample identifier and checked parameters.
URS-008The documentation shall support IQ/OQ/PQ preparation and inspection discussion.MediumURS, FS, CSV/JSON contract and test scenarios are supplied with the utility.
URS-009The utility shall support batch processing of multiple input.csv rows.MediumEach row is evaluated independently; errors in one row do not mask errors in others.
URS-010The utility shall support a simple operating model: demo mode and execution with input/output files.MediumThe CLI scenario is reproducible in test and production environments.

input.csv contract

#FieldTypeSamplePurpose
1BatchNumberstringPEPMAP-CE-2026-001Batch or lot identifier used for traceability, review and deviation investigation.
2PeakCountinteger45Controlled input parameter used by deterministic QC rules and traceable result generation.
3Coverage%decimal98.5Controlled input parameter used by deterministic QC rules and traceable result generation.
4Correlationstring / decimal0.995Controlled input parameter used by deterministic QC rules and traceable result generation.
5MainArea%decimal100.0Controlled input parameter used by deterministic QC rules and traceable result generation.
6NovelPeaksstring / decimal0Controlled input parameter used by deterministic QC rules and traceable result generation.
BatchNumber,PeakCount,Coverage%,Correlation,MainArea%,NovelPeaks
PEPMAP-CE-2026-001,45,98.5,0.995,100.0,0
PEPMAP-CE-2026-002,44,97.8,0.992,99.5,0
PEPMAP-FAIL-2026-003,30,85.0,0.920,95.0,3

FS — Functional Specification

IDFunctionImplementation
FS-001CSV importRead input.csv in UTF-8/CSV-compatible format and validate the header and expected columns.
FS-002Schema validationCheck mandatory fields, column count, critical missing values and row structure.
FS-003Type conversionConvert numeric, flag and text values; invalid formats are recorded as row-level errors.
FS-004Domain rule engineApply domain rules for CE Peptide Map Fingerprint, including limits from the utility description and approved specification.
FS-005Status aggregationProduce final status: FAIL for critical failure, WARNING for non-critical deviation, PASS for conformance.
FS-006JSON exportWrite output.json with detailed checks, source values, warnings, failures and critical findings.
FS-007Audit supportKeep the result structure suitable for review, deviation investigation, calculation reproduction and IQ/OQ/PQ preparation.
FS-008Integration contractSupport the production scenario: LIMS/ELN/MES creates input.csv, the utility returns output.json, and the portal displays description and documentation.
FS-009Error handlingReport errors unambiguously and do not substitute missing values with calculated values unless the rule is explicitly defined.
FS-010Version control supportDocument the utility version, input contract, executable checksum and rule application date.

Example output.json

{
  "utilityId": "ce-peptide-map-fingerprint",
  "utilityName": "CE_Peptide_Map_Fingerprint",
  "overallStatus": "PASS|WARNING|FAIL",
  "sourceFile": "input.csv",
  "checks": [
    {
      "parameter": "BatchNumber",
      "value": "PEPMAP-CE-2026-001",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "PeakCount",
      "value": "45",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Coverage%",
      "value": "98.5",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "Correlation",
      "value": "0.995",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "MainArea%",
      "value": "100.0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    },
    {
      "parameter": "NovelPeaks",
      "value": "0",
      "status": "PASS|WARNING|FAIL",
      "message": "Rule-based check result"
    }
  ],
  "criticalFindings": [],
  "warnings": [],
  "generatedFor": "QA/QC review and LIMS integration"
}

Traceability matrix

URSFSOQ/PQ coverage
URS-001, URS-003FS-001, FS-002, FS-003OQ-001/OQ-002/OQ-003
URS-002, URS-004FS-004, FS-005OQ-004/PQ-001
URS-005, URS-007FS-006, FS-007OQ-005/PQ-002
URS-008, URS-010FS-008, FS-010IQ-001/OQ-006

OQ/PQ test scenarios

IDScenarioExpected result
OQ-001Valid sample rowPASS or acceptable WARNING according to the rules.
OQ-002Mandatory column missingSchema error or FAIL.
OQ-003Non-numeric value in numeric fieldType-conversion error.
OQ-004Critical parameter outside limitFAIL and critical finding.
OQ-005Multiple rows with different statusesIndependent row-level evaluation.
PQ-001User real batch/sampleReviewed result with retained input/output files.

QA/QC and change control

  • Do not rename columns without updating the validator, documentation and test set.
  • Retain input.csv, output.json, executable version, documentation and checksum.
  • Before production use, perform IQ/OQ/PQ or equivalent CSV/CSA verification.
  • Critical limits must be verified against the approved specification, local SOPs and registration dossier.

Included in packages

Biopharmaceuticals Extended QC Suite

Extended QC utility coverage for mAbs, biosimilars, proteins, insulins, vaccines, mRNA/LNP, HCP, sterile release, microbiology, water, cleanroom and stability workflows.

Open

Diabetes QC Suite

QC package for diabetes medicines: insulins, metformin, SGLT2/DPP-4/GLP-1 products, glucagon and supporting dosage-form quality checks.

Open

Endocrinology QC Suite

QC package for endocrinology: thyroid, pituitary/peptide hormones, corticosteroids, sex hormones and selected metabolic medicines.

Open

Gastroenterology QC Suite

QC package for gastroenterology: PPIs, antiemetics, prokinetics, IBD medicines, laxatives, enzymes and GI anti-infectives.

Open

Immunology QC Suite

QC utility package for immunology: monoclonal antibodies, biosimilars, immunomodulators, immunosuppressants, ELISA/SPR, HCP, protein characterization, sterility and pyrogen/release checks.

Open

Lumex QC Suite

A single Lumex package combining the former Lumex and Lumex2 sets: instrumental and general pharmaceutical QC, AAS/ICP, CE, HPLC, NIR/PAT, stability, dissolution, content uniformity, system suitability and statistical control.

Open

Radiology QC Suite

QC package for radiology and diagnostic imaging: radiopharmaceuticals, PET/SPECT, contrast media, iodinated and gadolinium products, plus particle, sterility and endotoxin checks.

Open